ESR1 and breast cancer: Notably, studies on breast cancer [30] have demonstrated higher ceramide levels in estrogen receptor-positive breast cancer compared to estrogen receptor-negative cases, suggesting that increased sphingolipid concentrations may correlate with lower tumor aggressiveness.